valbenazine: Clinical Trials

7 completed, 1 enrolling by invitation, 1 terminated. 9 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	9	Completed 7, Enrolling by invitation 1, Terminated 1

Follow valbenazine: new trials by email Literature Review of valbenazine trials Research Report on valbenazine

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada Valbenazine - Chorea, Huntington	Phase 3	Enrolling by invitation	Neurocrine Biosciences	7	2024-04-24	2026-06-18
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Valbenazine, Placebo - Schizophrenia	Phase 3	Terminated	Neurocrine Biosciences	8	2023-01-05	2024-11-12
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy Placebo, Valbenazine - Dyskinesia, Cerebral Palsy	Phase 3	Completed	Neurocrine Biosciences	86	2022-04-15	2026-04-29
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia Placebo, Valbenazine - Schizophrenia	Phase 3	Completed	Neurocrine Biosciences	442	2021-11-29	2026-02-10
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease Valbenazine - Chorea, Huntington	Phase 3	Completed	Neurocrine Biosciences	154	2020-09-18	2026-06-17
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease Valbenazine, Placebo - Chorea, Huntington	Phase 3	Completed	Neurocrine Biosciences	128	2019-11-13	2023-10-11
Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia Valbenazine - Tardive Dyskinesia	Phase 3	Completed	Neurocrine Biosciences	161	2016-06-13	2018-12-19
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia NBI-98854 - Tardive Dyskinesia	Phase 3	Completed	Neurocrine Biosciences	167	2015-03-01	2018-11-30
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia NBI-98854, Placebo - Tardive Dyskinesia	Phase 3	Completed	Neurocrine Biosciences	234	2014-10-01	2017-07-11

Conditions studied

Huntington Disease (3)  ·  Tardive Dyskinesia (3)  ·  Chorea (2)  ·  Schizophrenia (2)  ·  Athetosis (1)  ·  Cerebral Palsy (1)  ·  Dyskinesias (1)  ·  Dystonia (1)  ·  Movement Disorders (1)

Sponsors

Neurocrine Biosciences (9)

Countries

United States (8)  ·  Canada (5)  ·  Argentina (2)  ·  Puerto Rico (2)  ·  Belgium (1)  ·  Brazil (1)  ·  Bulgaria (1)  ·  Israel (1)  ·  Italy (1)  ·  Mexico (1)  ·  Poland (1)  ·  Portugal (1)  ·  Serbia (1)  ·  Spain (1)

Top investigators

Chris O'Brien, MD (1)

Results publications

PMID 31617235, PMID 40265997, PMID 28320223, PMID 28404690, PMID 29141124, PMID 30695293, PMID 32250312, PMID 32419679, PMID 37210099